TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01273701

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial intervention
Description: The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1.
Study: NCT02466087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mg Cl
Description: Four supplements a day for 6 weeks.
Study: NCT02564016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Infusion
Description: Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capped Epidural
Description: epidural will be capped with no saline infusion.
Study: NCT01273701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone reminding
Description: Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
Study: NCT04363762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based multimodal pain program
Description: A guided internet-based multimodal pain program for chronic TMD pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splint
Description: Occlusal splint, standard
Study: NCT04223362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based physical activity programme
Description: After completing a pulmonary rehabilitation programme, participants will enrol a 6-months personalised community-based physical activity programme, which will include 2 sessions/week, with the aerobic training being the cornerstone. Patients will receive the PICk UP manual and a diary to register their physical activities. During the 1st month the physiotherapist will guide patients through 4 types of outdoors and indoors physical activities. Patients will then be asked to choose and commit to 1 or 2 activities, according to their preferences, which they shall integrate for another 5 months. During this period, the support provided by physiotherapist will decrease over time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
Study: NCT03014687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
Description: Oral antibiotics (cefdinir \[Omnicef®\] 300 mg PO BID or trimethoprim/sulfamethoxazole \[Bactrim DS™\] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
Study: NCT01766167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: Low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: Middle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: High

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: Multiple
Study: NCT02890693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interdisciplinary lifestyle and psychosocial intervention
Description: The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
Study: NCT01588704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Bevacizumab
Description: Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
Study: NCT04241796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Cancer Early Detection Test
Description: Blood collection and multi-cancer early detection testing with return of results.
Study: NCT03780309

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Self-Monitoring
Description: Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Self-Monitoring
Description: Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Pressure Self-Monitoring
Description: Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
Study: NCT00454662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan medoxomil / amlodipine or azelnidipine
Description: AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan medoxomil / low dose thiazide type drug
Description: AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
Study: NCT02601703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Ointment 0.1%
Description: apply thin layer of ointment to affected area

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic® ointment, 0.1%
Description: apply thin layer of ointment to affected area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Tacrolimus Ointment
Description: apply thin layer of ointment to affected area
Study: NCT01801319

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Libra Deep Brain Stimulation System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Libra Deep Brain Stimulation System
Study: NCT02837380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI/UMEC
Description: VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
Study: NCT02282527

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Liquid Alpha₁-PI
Description: Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Liquid Alpha₁-PI
Description: Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prolastin-C
Description: Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prolastin-C
Description: Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
Study: NCT03735771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.25% bupivacaine plus fentanyl 8 mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.25% bupivacaine plus fentanyl 8 mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.25% bupivacaine plus fentanyl 8 mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.25% bupivacaine plus fentanyl 8 mcg/ml
Study: NCT04097899

Intervention type: OTHER
Intervention: implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients
Description: Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~* Antibiotics cost.~* Appropriates of antibiotic use (initiation, duration \& time of discontinuation).~* Rate of resistance~* Clinical outcome, infection rate \&length of stay.
Study: NCT04782999

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Standard test of glucose tolerance with ingestion of 75 g glucose followed by blood sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemic clamp with infusion of saline, GLP-1 or GIP
Description: Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~* Saline~* GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~* GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemic clamp with infusion of saline, GLP-1 or GIP
Description: Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~* Saline~* GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~* GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemic clamp with infusion of saline, GLP-1 or GIP
Description: Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~* Saline~* GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~* GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min).
Study: NCT03031756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glycine powder air-polishing (Air-Flows)Perio Powder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)
Study: NCT00883350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RIDE e-health application
Description: The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
Study: NCT02405390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy
Description: Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz C-Mac® laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz C-Mac® laryngoscope
Study: NCT02183142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobic, China, 7.5 mg
Study: NCT02374333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19
Study: NCT02183142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic, China, 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobic, Germany, 7.5 mg
Study: NCT02616263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot exercise
Study: NCT02183142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic, Germany, 7.5 mg
Study: NCT01864941

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter venography with balloon venoplasty
Description: All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Catheter venography with balloon venoplasty
Description: All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter venography with balloon venoplasty and balloon
Study: NCT00821483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Frovatriptan
Description: 2.5mg, qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frovatriptan
Description: 2.5mg, qd
Study: NCT01689103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Description: Cognitive-behavioral treatment of alcohol use disorders

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-behavioral treatment
Description: Cognitive-behavioral treatment of alcohol use disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Description: Cognitive-behavioral treatment for alcohol use disorders

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-behavioral treatment
Description: Cognitive-behavioral treatment for alcohol use disorders
Study: NCT00993681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TD Vaccine System
Description: heat labile enterotoxin of E. coli (LT)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TD Vaccine System
Description: placebo
Study: NCT03844100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efficacy and safety of CNU® Capsule
Description: All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
Study: NCT03316365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS)
Description: The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Auditory Stimulation (RAS)
Description: The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
Study: NCT03344796

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal attainment
Description: After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal attainment
Description: After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.
Study: NCT03629210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZURDEX
Description: OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZURDEX
Description: OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eylea
Description: EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
Study: NCT01635335

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Latino STYLE
Description: 7-hour family-based workshop with 3-hour follow-up booster 3 months later

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Latino STYLE
Description: 7-hour family-based workshop with 3-hour follow-up booster 3 months later
Study: NCT01826071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Elongation